New hope for kids with incurable brain cancer: First-in-Human trial launches
NCT ID NCT07087002
Summary
This early-stage trial is testing a new type of personalized cell therapy for children and young adults whose aggressive brain tumors have come back or not responded to standard treatments. Doctors take a patient's own immune cells, genetically modify them to target a protein (GPC2) on the tumor, and infuse them directly into the fluid around the brain. The main goals are to see if making and giving these cells is safe and feasible, and to look for early signs that they might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MEDULLOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lucile Packard Children's Hospital Stanford
RECRUITINGPalo Alto, California, 94304, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.